Introduction
Bacterial bloodstream infections are a leading cause of morbidity and mortality worldwide. 1 In the United States approximately 200 000 patients develop bacteraemia or fungaemia annually with estimated associated mortality ranges of 20 to 50%, and septicaemia is the 13th leading cause of death. 1, 2 In addition, antimicrobial resistance in some of the most frequent bacterial species isolated from blood such as Staphylococcus aureus or Streptococcus pneumoniae has reached worrying levels. 3 National surveillance programmes are required to follow (i) the distribution of bacterial species among bloodstream isolates, and (ii) the antimicrobial susceptibility of the pathogens in order to adapt empirical antibiotic strategies. In this report we describe the frequency of isolation of bacteria from blood cultures during 1 month in a large network of French hospital laboratories and susceptibility of these isolates to various antibiotics.
Materials and methods

Study design
The Collège de Bactériologie-Virologie Hygiène des Hôpi-taux (ColBVH study group) is a broad network of 105 nonteaching sentinel hospitals equally geographically distributed and representative of general hospitals in France. General data about size and activities of participating hospitals are listed in Table 1 . One of the aims of the network is to monitor the predominant pathogens responsible for blood infections diagnosed in hospitals and their antimicrobial resistance patterns. All non-duplicate bloodstream strains isolated during a 1 month period (9 October 2000 to 4 November 2000) were sent to a central laboratory (Centre Hospitalier de Versailles).
Only blood culture isolates judged to be clinically relevant by national guidelines which refer to the recommendation of Centers for Disease Control and Prevention were included. 4 No patient age limitations were imposed.
Bacterial identification
Blood culture isolates were identified at the participating institutions by the local routine methodology. Upon receipt at the central laboratory, species identification was carried out (detection of IS431 and femA genes by PCR for S. aureus, optochin susceptibility test for S. pneumoniae). 5 
Antimicrobial susceptibility testing
Data obtained by disc susceptibility tests according to the NCCLS guidelines and by the Etest method (AB Biodisk, Sweden) were collected. 6,7 ESBL production was detected by means of double-disc synergy tests and phenotypic confirmatory tests as recommended by the NCCLS. 
Clonality of strains
The clonal relationship was studied by pulsed-field gel electrophoresis (PFGE) for MRSA strains and serotype determination by the Quellung reaction using type-specific rabbit antisera from the Statens serum Institut, Copenhagen, Denmark for pneumococci. 12 Cross-reactivity of serotypes within the same serogroup was assumed in the analysis of the theoretical coverage by the vaccines.
Sequence determination of the quinolone resistancedetermining regions (QRDRs) of gyrA, gyrB, parC and parE
Portions of genes from pneumococcal strains highly resistant to fluoroquinolones (MIC of gatifloxacin ≥2 mg/L) were amplified by PCR as previously described. 13 Independently obtained amplification products were purified with the QIAquick PCR purification kit (Qiagen) and sequenced on both strands by ABI Prism d-Rhodamine terminator cycle sequencing and an ABI 310 automated sequencer (PerkinElmer, Applied Biosystems, USA). Sequence analysis was carried out using BLAST software (www.ncbi.nlm.nih.gov).
Results
The distribution of the bacterial species of the 1463 strains collected is reported in Table 2 . During data analysis, no significant differences about species distribution or antimicrobial resistance frequencies between centres were established (data not shown). The results of the quality control showed 97% agreement between the participating laboratories and the reference centre with regard to the susceptibility categorization. Among bloodstream isolates, 45.8% were Gram-positive bacteria (16.5% S. aureus, 9.5% streptococci except pneumococci, 8.3% coagulase-negative staphylococci, 7.7% S. pneumoniae and 3.8% enterococci) and 54.2% Gram-negative bacteria (Enterobacteriaceae group 1, 38.4%; group 2, 4.6%; group 3, 5.6% and non-Enterobacteriaceae, 5.6%). Among the 242 S. aureus, 87 were MRSA (Table 3 ) and their range of MICs, MIC 50 and MIC 90 are reported in Table 4 . Gentamicin-resistant strains represented 11.5% of the MRSA. One strain was highly resistant to quinupristin/dalfopristin and all but one strain were resistant to ciprofloxacin. MICs of gatifloxacin were lower than those of ciprofloxacin. By agar dilution, all strains were susceptible to vancomycin. One strain was not susceptible to teicoplanin (MIC = 16 mg/L). Ten strains that grew on the screen plates were analysed for resistant subpopulations and seven showed significant resistant subpopulations on both vancomycin and teicoplanin containing plates. They were classified as heteroresistant to both glycopeptides and were also resistant to gentamicin. 14 No glycopeptide homogeneous resistant strain was identified.
Data obtained by PFGE indicated that 12 MRSA clones had disseminated in French hospitals, six of them also being heterogeneously resistant to vancomycin (Figure 1 ). The six hetero-VRSA strains were isolated in six hospitals from distinct areas; they belonged to MRSA clones that also included glycopeptide susceptible strains.
The antimicrobial susceptibility of the streptococci, enterococci species and S. pneumoniae is summarized in Tables 5, 6 and 7, respectively. All enterococci strains were susceptible to glycopeptides.
The distribution of S. pneumoniae serotype was as follows: 14 (18.6%), 1 (8.8%), 4 (6.9%), 23-F (6.9%), 24 The results of susceptibility testing and MIC determination for Enterobacteriaceae recovered from blood cultures are summarized in Table 8 . Gentamicin, cefotaxime, ciprofloxacin and gatifloxacin susceptible strains represented 95% of the isolates. Ten isolates produced an extended spectrum β-lactamase: Citrobacter freundii (n = 1), Enterobacter aerogenes (n = 4), Enterobacter cloacae (n = 1), Escherichia coli (n = 3) and Klebsiella pneumoniae (n = 1).
The results for Pseudomonas aeruginosa strains recovered from blood cultures are summarized in Table 9 . Ciprofloxacin and gentamicin resistance were established in about 25% of P. aeruginosa strains. No strain was found to produce an ESBL by antimicrobial susceptibility testing.
Discussion
The control of emergence and spread of antimicrobial resistance among the most common human bacterial pathogens is probably one of the most important challenges for the scientific and medical community. Several national or international surveillance networks aimed at providing data on antimicrobial susceptibility of the major bacterial pathogens, collected by species or site of isolation. 15, 16 Bloodstream isolates are the best candidates for the study of pathogenic bacterial species, in particular, those that are responsible for human colonization such as S. aureus, S. pneumoniae or E. coli. 17 In this study, the distribution of bacterial species showed similarities with previous reports: the top three bacterial species were E. coli, S. aureus and coagulase-negative staphylococci. 15, 16, 18 However, the ranking of S. pneumoniae seems to be higher in France than in other countries. S. pneumoniae was the fourth bacterial species isolated from blood cultures representing 7.7% of bloodstream strains whereas it was ranked eleventh (2.3% of blood cultures isolates) in the European SENTRY study and seventh (4.8%) in the USA, Canada and Latin America by the same network. 15, 16 This difference is surprising since the incidence of invasive pneumococcal diseases in young children is higher in North America than in western Europe. 19 However, seasonal variation with a high incidence of S. pneumoniae bacteraemia during the winter months during the study period (October-November) could have artificially increased the frequency of pneumococcal bacteraemia. 20 In contrast, and as already reported by several European networks, the ranking of enterococci was lower in this study than in North American reports. 15, 16 Coagulase-negative staphylococci ranked third, as in other European or American studies, however their role in bacteraemia remains controversial. 15, 16, 21 Among S. aureus, the incidence of resistance to methicillin was 36%, similar to that observed by the Centers for Disease Control and a British network (34%) but higher than previous results from other European countries (23.8%). 15, 16, 22 The MRSA were susceptible to gentamicin (88.5%), in contrast to 22.8% reported in Europe, but were resistant to fluoroquinolones as reported previously. 22 Glycopeptides are the main antimicrobial agents for therapy of infections due to MRSA and emergence and spread of VRSA are thus of great concern; the vanA carrying strains have been recently detected. 23, 24 To the best of our knowledge, this work is the first national French prospective study that investigates glycopeptide susceptibility of bloodstream isolates of MRSA using a well-established screening test and confirming methods. The frequency of hetero-VRSA strains (8%) was higher than that reported in the UK and Wales (0%) but very similar to that in Germany (8.2%). 25, 26 Gentamicin-resistant strains appeared to be particularly common in French VRSA. The high percentage of VRSA susceptible to quinupristin/dalfopristin was also reported in a recent worldwide study. 27 In the few outbreaks of VRSA reported in French hospitals, a low number of clones were implicated. 28, 29 However, the Lower respiratory tract infections are a major cause of morbidity and mortality. Among the bacterial species implicated, S. pneumoniae is the most life threatening in particular for patients with bacteraemic pneumonia. 31 In this study, there was a high diversity of serotypes but the clinical importance of serotypes 1 (8.8%), 4 (6.9%) and 24-F (5.9%) has not been previously stressed in France. 32 Type 1 serotype has a high capacity of spread. In Denmark, it caused 26.5% of all invasive pneumococcal infections in 1996 and in a recent study accounted for 50% of the cases of pneumococcal empyema in children, one of the most serious complications of pneumonia. 33, 34 The 7-valent conjugated vaccine covers 55.9% of the serotypes isolated in our study. The future 9-valent vaccine that includes serotypes 1 and 5 would cover 64.7% of the isolates and the 11-valent 73.5%. The consequences of lack of types 1 and 24-F in the recently available 7-valent vaccine should be investigated.
The rate of penicillin non-susceptible S. pneumoniae increased from 37.2% in 1999 to 43% in our study. 35 The number of highly penicillin-resistant isolates doubled during this period (10.6% versus 23%). These results set France in the group of leading countries for penicillin-resistant pneumococci, next to Spain, although in our country there are no strains highly resistant to ceftriaxone, as opposed to 6.8% in Spain. 18, 36, 37 The reasons for this difference remain unknown. The high number of erythromycin-resistant strains was not a surprise because of co-resistance to macrolides and the penicillins. Concerning the fluoroquinolones, the MIC 90 of ciprofloxacin was low (2 mg/L), as already reported for Spain (2 mg/L) and the USA (1 mg/L). 37, 38 A single double mutant showed high-level resistance to fluoroquinolones and had mutations previously described in clinical isolates. 39, 40 As opposed to neighbouring countries, no vancomycinresistant enterococci were detected. 15, 18 Imipenem was the most active antibiotic against P. aeruginosa (92% susceptible strains) followed by ceftazidime (87%) and ciprofloxacin (72%). Carbapenem-hydrolysing enzymes encoded by mobile elements have already spread in France, Italy and Greece. 41 Gentamicin resistance was as frequent as in other European studies, representing about one-quarter of the isolates, but higher than the percentage established in North American studies. 15, 16 Amongst Enterobacteriaceae, cefotaxime, gentamicin and ciprofloxacin showed the highest rates of in vitro efficiency and ciprofloxacin and gatifloxacin displayed similar in vitro activity. The incidence of ESBL-producing isolates was quite low, in particular for K. pneumoniae (1/66). In another European study, 16.7% of strains isolated during 1997-1998 putatively encoded such enzymes. 15 The percentage of strains of Enterobacteriaceae susceptible to ciprofloxacin is stable and similar to other nationwide surveys. 15, 16 
Conclusions
It is essential to evaluate prospectively the distribution of bacterial species isolated from blood and their susceptibility to the major antimicrobial agents and alternative drugs to adapt antibiotic therapy strategies. The high percentages of MRSA and penicillin-resistant S. pneumoniae result in frequent use of glycopeptides, third-generation cephalosporins and new fluoroquinolones. 42, 43 However, in France as in other countries, isolation of a VRSA strain or of fluoroquinoloneresistant S. pneumoniae should not be considered as an exceptional event. Identification of VRSA-infected patients and carriers, and control measures are needed to avoid the local spread of such strains. The few clones of these bacterial species currently circulating should be monitored. The risk of 
